Survey Shows High Awareness and Potential for Rapid Adoption
QUEBEC CITY, June 14, 2012 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a
Quebec life sciences company that develops and commercializes
high-value cancer diagnostic tests, today announced that LifeSci
Advisors, LLC, a leading provider of investment research and investor
relations services in the life sciences sector, has published an
independent survey of 273 practicing urologists who answered within two
days on their expected use of the PCA3 assay in men suspected of having
"Based on the results of our proprietary survey we believe there is
strong interest in the use of the test by both academic and community
based urologists" said Andrew I. McDonald, Ph.D., Founding Partner at
LifeSci Advisors. "Almost half (49.6%) of the survey responders intend
to test their patients with this assay, 47.4% report that they may use
it, and only 4.1% do not expect to use the test."
DiagnoCure Inc. owns the exclusive worldwide diagnostic rights to the
PCA3 marker which predicts the results of repeat biopsies more
accurately than traditional PSA serum tests, known to have very high
false positive rates. PCA3 identify patient at risk of prostate cancer
following a first prostate biopsy and may help reduce unnecessary
repeat prostate biopsies. DiagnoCure receives royalties on worldwide
sales of the test.
Dr. McDonald's full Survey Report is available to download at no cost on
the LifeSci Advisors website at http://lifesciadvisors.com/marketresearch/ and can also be accessed from DiagnoCure's website at
www.diagnocure.com, through the hyperlink under the "Analysts" page of
the "Investors" tab.
About LifeSci Advisors
LifeSci Advisors (LSA) is a leading research firm and communications
consultancy dedicated to the life sciences industry. The firm provides
strategic counsel, customized marketing communications, comprehensive
research reports and investor relations services to companies that
specialize in the discovery, development and commercialization of
drugs, drug delivery systems, medical devices and diagnostics. To
learn more about LSA, visit the company's website, www.lifesciadvisors.com.
DiagnoCure (TSX: CUR) is a life sciences company that develops and
commercializes high-value cancer diagnostic tests that increase
clinician and patient confidence in making critical treatment
decisions. In 2008, the Company launched the PrevistageTM GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and
granted the worldwide exclusive rights to this test to Signal Genetics
in June 2011. The Company has also granted a worldwide exclusive
license agreement to Gen-Probe (NASDAQ: GPRO) for the development and
commercialization of a second-generation prostate cancer test using
PCA3, DiagnoCure's proprietary molecular biomarker. Gen-Probe's
PROGENSA® PCA3 test is commercialized in Europe under CE mark and is
now approved for commercialization in Canada and the United States. For
more information, visit www.diagnocure.com.
This release contains forwardlooking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. By their very nature,
forwardlooking statements are based on expectations and hypotheses and
also involve risks and uncertainties, known and unknown, many of which
are beyond DiagnoCure's control. As a result, investors are cautioned
not to place undue reliance on these forwardlooking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure's
most recent Annual Information Form under the heading "Risk Factors".
DiagnoCure undertakes no obligation to publicly update or revise any
forwardlooking statements contained herein unless required by the
applicable securities laws and regulations.
SOURCE DIAGNOCURE INC.